IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Immunology

• Publication date

  2005-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CLIM.2005.01.011PMID 15885646
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High levels of neutralizing IL‐6 autoantibodies in 0.1% of apparently healthy blood donors

  2004cited by this paper
• Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology.

  2003cited by this paper
• Serum Interleukin-6 Reflects Disease Severity and Osteoporosis in Mastocytosis Patients

  2002cited by this paper
• Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase.

  2002cited by this paper
• Serum levels of IL‐6 and its soluble receptor (sIL‐6R) in Waldenström's macroglobulinemia

  2001cited by this paper
• The soluble IL-6 receptors: serum levels and biological function.

  2001cited by this paper
• Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease.

  2001cited by this paper
• Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes.

  2001cited by this paper
• The soluble IL-6 receptors: serum levels and biological function.

  2001cited by this paper
• Mastocytosis: molecular mechanisms and clinical disease heterogeneity.

  2001cited by this paper
• Clinical and Biologic Diversity of Leukemias Occurring in Patients with Mastocytosis

  2000cited by this paper
• Hematologic aspects of systemic mastocytosis.

  2000cited by this paper
• Lymphoid tissues and the immune system in mastocytosis.

  2000cited by this paper
• Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology.

  2000cited by this paper
• World Health Organization classification of tumors

  2000cited by this paper
• Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

  1999cited by this paper
• Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies.

  1997cited by this paper
• Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.

  1997cited by this paper
• Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.

  1996cited by this paper
• The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL- 6 and prolongation of the plasma half-life of IL-6

  1996cited by this paper
• Interleukin-6-Type Cytokines In Vivo: Regulated Bioavailability 1

  1996cited by this paper
• Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells.

  1996cited by this paper
• Interleukin-6 in human multiple myeloma.

  1995cited by this paper
• Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells.

  1995cited by this paper
• Heterogeneity of human mast cells based on cytokine content.

  1995cited by this paper
• The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis.

  1995cited by this paper
• Interleukin-6 and selected plasma proteins in healthy persons of different ages.

  1994cited by this paper
• Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.

  1993cited by this paper
• Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

  1993cited by this paper
• Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus

  1992cited by this paper
• Leukocytosis in mice following long-term reconstitution with genetically-modified bone marrow cells constitutively expressing interleukin 1 alpha or interleukin 6.

  1991cited by this paper
• Biological and clinical aspects of interleukin 6.

  1990cited by this paper
• Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa

  1990cited by this paper
• Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

  1990cited by this paper
• Correlation of synovial fluid interleukin 6 (IL-6) activities with IgG concentrations in patients with inflammatory joint disease and osteoarthritis.

  1989cited by this paper
• A possible autocrine role for interleukin-6 in two lymphoma cell lines.

  1989cited by this paper
• Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control.

  1989cited by this paper
• Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

  1989cited by this paper
• Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia.

  1989cited by this paper
• Interleukin 6 gene expression in normal and neoplastic B cells.

  1989cited by this paper
• Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

  1988cited by this paper
• Systemic Mast Cell Disease: ANALYSIS OF 58 CASES AND LITERATURE REVIEW

  1988cited by this paper

• Gut-Brain Inflammation and Disrupted Homeostasis Due to Activation of Mast Cells and Microglia.

  2026cites this paper
• Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial

  2025cites this paper
• Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges

  2025cites this paper
• Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

  2024cites this paper
• Luteolin Is More Potent than Cromolyn in Their Ability to Inhibit Mediator Release from Cultured Human Mast Cells

  2024cites this paper
• Cognitive Impairment and Depression in Mastocytosis: A Synthesis of the Literature

  2024cites this paper
• The prevalence of osteoporosis is low in adult cutaneous mastocytosis patients.

  2024cites this paper
• Crosstalk Between Mitochondrial DNA and Immune Response: Focus on Autism Spectrum Disorder

  2024cites this paper
• Mast Cells: The Unregulated Master Immune Response Conductor

  2024cites this paper
• A proteomic and transcriptomic screening demonstrate increased mast cell-derived CCL23 in systemic mastocytosis.

  2023cites this paper
• Mast Cells in the Autonomic Nervous System and Potential Role in Disorders with Dysautonomia and Neuroinflammation.

  2023cites this paper
• Potential Role of Moesin in Regulating Mast Cell Secretion

  2023cites this paper
• Genetic variants leading to urticaria and angioedema and associated biomarkers.

  2023cites this paper
• Childhood Cutaneous Mastocytosis: Revisited

  2023cites this paper
• Secretory and Membrane-Associated Biomarkers of Mast Cell Activation and Proliferation

  2023cites this paper
• Mast cell activation: beyond histamine and tryptase

  2023cites this paper
• Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID

  2023cites this paper
• Non-Tryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.

  2022cites this paper
• Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User´s Guide for Daily Clinical Practice.

  2022cites this paper
• Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?

  2022cites this paper
• New Insights Into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.

  2022cites this paper
• Contribution of the Microbiome, Environment, and Genetics to Mucosal Type 2 Immunity and Anaphylaxis in a Murine Food Allergy Model

  2022cites this paper
• Cutaneous Mastocytosis in Childhood—Update from the Literature

  2021cites this paper
• Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021

  2021cites this paper
• Neuroimmune connections between corticotropin-releasing hormone and mast cells: novel strategies for the treatment of neurodegenerative diseases

  2021influential citation
• Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis

  2021cites this paper
• Pediatric Mastocytosis: An Update

  2021cites this paper
• Bidirectional communication between mast cells and the gut-brain axis in neurodegenerative disease: avenues for therapeutic intervention.

  2021cites this paper
• Long‐COVID syndrome‐associated brain fog and chemofog: Luteolin to the rescue

  2021cites this paper
• Mastocytosis: A Comprehensive Guide

  2020influential citation
• Impaired endothelial function irrespective of systemic inflammation or atherosclerosis in mastocytosis.

  2020cites this paper
• Emerging mechanisms contributing to mast cell-mediated pathophysiology with therapeutic implications.

  2020cites this paper
• Targeting Mast Cells with Biologics.

  2020cites this paper
• Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production

  2020cites this paper
• KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6

  2020influential citation
• Expression of suppressor of cytokine signaling 3 (SOCS3) and interleukin-6 (-174-G/C) polymorphism in atopic conditions

  2019cites this paper
• Effect of IL-33 on de novo synthesized mediators from human mast cells.

  2019cites this paper
• Multiple vertebral fractures as the first manifestation of systemic mastocytosis

  2019cites this paper
• Recent advances in our understanding of mast cell activation – or should it be mast cell mediator disorders?

  2019cites this paper
• Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.

  2019cites this paper
• Mast Cells in Cardiovascular Disease: From Bench to Bedside

  2019cites this paper
• Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis

  2019cites this paper
• Systemic Mastocytosis and Bone-Related Events

  2019cites this paper
• Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis.

  2018cites this paper
• The JAK1/JAK2‐ inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release

  2018cites this paper
• Regulation Of Prostaglandin D2 And Angiogenesis-Related Factors From Human Skin Mast Cells By Interleukin-6 And Resveratrol

  2018cites this paper
• Interleukin-6 potentiates FcεRI-induced PGD2 biosynthesis and induces VEGF from human in situ-matured skin mast cells.

  2018cites this paper
• Diagnostic Problems in Chronic Basophilic Leukemia

  2018cites this paper
• Mastocytosis-derived extracellular vesicles exhibit a mast cell signature, transfer KIT to stellate cells, and promote their activation

  2018influential citation
• Lower prevalence of vitamin D insufficiency in German patients with systemic mast cell activation syndrome compared with the general population

  2017cites this paper
• The Tryptase Test Clinical Use in Dermatology and Allergy

  2017cites this paper
• Pathogenesis and Pathology of Mastocytosis.

  2017cites this paper
• Hymenoptera-induced anaphylaxis: is it a mast cell driven hematological disorder?

  2017cites this paper
• CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

  2017cites this paper
• Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders

  2016cites this paper
• Association of IL-6 Promoter and Receptor Polymorphisms with Multiple Myeloma Risk: A Systematic Review and Meta-Analysis

  2016cites this paper
• IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3.

  2016cites this paper
• Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis

  2016cites this paper
• Brain Fires in Autism Spectrum Disorders

  2016cites this paper
• Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis

  2016influential citation
• Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression

  2016cites this paper
• IL-6 promotes an increase in human mast cell number and reactivity through suppression of SOCS3

  2016cites this paper
• Urinary 11β‐PGF2α and N‐methyl histamine correlate with bone marrow biopsy findings in mast cell disorders

  2015cites this paper
• Oxidative stress markers are increased in patients with mastocytosis

  2015cites this paper
• Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms

  2015cites this paper
• Bone morbidity in chronic myeloproliferative neoplasms

  2015cites this paper
• Mast cell leukemia associated with undefined morphology and chronic basophilic leukemia

  2014cites this paper
• Bone involvement and osteoporosis in mastocytosis.

  2014cites this paper
• Epidemiology, prognosis, and risk factors in mastocytosis.

  2014cites this paper
• Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis.

  2014cites this paper
• Spectrum of mast cell activation disorders

  2014cites this paper
• A segmental rash in a young male: a quiz. Naevoid urticaria pigmentosa.

  2014cites this paper
• Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies

  2013cites this paper
• Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis

  2013cites this paper
• Comparative analysis of IL6 and IL6 receptor gene polymorphisms in mastocytosis

  2013influential citation
• Is a subtype of autism an allergy of the brain?

  2013cites this paper
• Anesthetic considerations in pediatric mastocytosis: a review

  2013cites this paper
• Notable Increased Cerebrospinal Fluid Levels of Soluble Interleukin-6 Receptors in Neuromyelitis Optica

  2012cites this paper
• Characterization and Function of Histamine Receptors in Human Bone Marrow Stromal Cells

  2012cites this paper
• High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis

  2012cites this paper
• Neuro-inflammation, blood-brain barrier, seizures and autism

  2011cites this paper
• Serum tryptase, interleukin 6 and SCORMA Index as disease severity parameters in childhood mastocytosis

  2010influential citation
• Mastozytose und Anaphylaxie - klinisch-experimentelle Untersuchungen zu Pathomechanismus und Auslösefaktoren

  2009cites this paper
• Clinical Aspects of Diffuse Cutaneous Mastocytosis in Children: Two Variants

  2009cites this paper
• Systemic mastocytosis: clinical manifestations and differential diagnosis.

  2006cites this paper